Regulation and functional significance of CDC42 alternative splicing in ovarian cancer
Metrics: PDF 609 views | HTML 874 views | ?
Xiaolong He1, Chengfu Yuan2, Jilai Yang1
1Department of Biopharmaceutical Sciences, College of Pharmacy-Rockford, The University of Illinois at Chicago, Rockford, IL 61107, USA
2Medical College of China Three Gorges University, Yichang, Hubei, 443002, People’s Republic of China
Xiaolong He, e-mail: firstname.lastname@example.org
Keywords: alternative splicing, PTBP1, CDC42, ovarian cancer
Received: November 20, 2014 Accepted: August 12, 2015 Published: August 22, 2015
Our previous study found that splicing factor polypyrimidine tract-binding protein 1 (PTBP1) had a role in tumorigenesis but the underlying mechanism remained unclear. In this study, we observed that knockdown of PTBP1 inhibited filopodia formation. Subsequently, we found that PTBP1 regulated the alternative splicing of CDC42, a major regulator of filopodia formation. Two CDC42 variants, CDC42-v1 and CDC42-v2, can be generated through alternative splicing. Knockdown of PTBP1 increased the expression of CDC42-v2. Ectopic expression of individual variants showed that CDC42-v2 suppressed filopodia formation, opposite to the effect of CDC42-v1. Quantitative RT-PCR revealed that CDC42-v2 was expressed at lower levels in ovarian cancer cell lines and ovarian tumor tissues than in normal control cells and tissues. Further, CDC42-v2 was observed to have inhibitory effects on ovarian tumor cell growth, colony formation in soft agar and invasiveness. In contrast, these inhibitory effects were not found with CDC42-v1. Taken together, above results suggest that the role of PTBP1 in tumorigenesis may be partly mediated by its regulation of CDC42 alternative splicing and CDC42-v2 might function as a tumor suppressor.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.